Magnesium Glycinate vs NSI-189

Mechanism

Magnesium is a cofactor for >600 enzymatic reactions including all ATP-dependent reactions (Mg-ATP is the true substrate), DNA/RNA polymerases, and ion channel regulation. Magnesium glycinate chelate provides highly bioavailable elemental magnesium bound to glycine. The glycine moiety itself is an inhibitory neurotransmitter (glycine receptors) and NMDA receptor co-agonist at the glycine binding site. The chelated form minimizes the osmotic laxative effect of ionic magnesium salts. Magnesium regulates NMDA receptor gating (voltage-dependent Mg2+ block), GABA-A receptor potentiation, HPA axis modulation, and parathyroid hormone secretion.

Standard Dosing

200-400mg elemental magnesium daily

Timing

Evening/bedtime (promotes relaxation and sleep quality). Can split AM/PM.

Cycle Duration

ongoing

Side Effects

• Drowsiness
• Mild GI discomfort
• Loose stools (less than other Mg forms)
• Hypotension at very high doses

Contraindications

• Severe renal insufficiency (impaired Mg excretion — risk of hypermagnesemia)
• Myasthenia gravis (Mg can worsen neuromuscular junction blockade)
• Heart block (Mg slows AV conduction)

Best Stacking Partners

Mechanism

Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.

Standard Dosing

40 mg once daily (for educational context — investigational compound, not approved for any indication)

Timing

Once daily, time of day not definitively established from clinical data. With or without food.

Cycle Duration

Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.

Side Effects

• Headache
• GI discomfort
• Dizziness
• Somnolence
• Dry mouth
• Generally well-tolerated in Phase 1b and Phase 2 trials

Contraindications

• Pregnancy and lactation (no safety data; neurogenic compounds carry theoretical teratogenic risk)
• History of brain tumors (neurogenic stimulation could theoretically promote growth — speculative)
• No regulatory approval for any indication — investigational use only

Best Stacking Partners